fb102

mAbexperimental

Clinical trial activity

3 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Mar 25, 2025 (NCT06905873)

Timeline

2020s

  1. Jan 1, 2025

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2025

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetINHIBITOR

    Inhibitor

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07205159Phase 1Oct 23, 2025Forte Biosciences, Inc.
NCT06982963Phase 2Aug 4, 2025Forte Biosciences, Inc.
NCT06905873Phase 1Mar 25, 2025Forte Biosciences, Inc.
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Forte Biosciences, Inc.For profit3322025
1 organizations
Page 1 / 1